{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-035208","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.464557+00:00","generated_at":"2026-05-16T19:54:02.650338+00:00","sec_items":["2.02","7.01","2.05","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Tivic Health winds down ClearUP consumer biz; Q3 net loss $2.6M","bullets":["Q3 revenue $146K (+16% YoY); gross loss $145K from $230K inventory reserve for ClearUP exit.","Net loss $2.6M vs $1.4M in Q3 2024; operating expenses rose to $2.3M on biopharma costs.","ClearUP wind down: $347K charge incurred, $20-50K more expected; minimal revenue until approval.","Transferred two INDs for Entolimod (neutropenia, cancer); cell line verification for cGMP completed.","Cash $3.5M; $3.5M available via preferred equity; no debt."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-035208","json":"https://secwatch.observer/filing/0001437749-25-035208.json","markdown":"https://secwatch.observer/filing/0001437749-25-035208.md","text":"https://secwatch.observer/filing/0001437749-25-035208.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000143774925035208/0001437749-25-035208-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000143774925035208/tivc20250909_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:54:02.650338+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}